Evaluation of Risk Minimisation Measures for Blood Components-Based on Reporting Rates of Transfusion-Transmitted Reactions (1997-2013)

Transfusion Medicine and Hemotherapy

Volumn 42, Issue 4, 2015, Pages 240-246

  Funk, Markus B ^a   Heiden, Margarethe ^a   Volkers, Peter ^a   Lohmann, Annette ^a   Keller Stanislawski, Brigitte ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

Author keywords

Blood components; Haemovigilance; Reporting rate; Risk minimisation measures; Transfusion reaction

Indexed keywords

FRESH FROZEN PLASMA; HEPATITIS B CORE ANTIGEN; HLA ANTIGEN CLASS 1; THROMBOCYTE CONCENTRATE;

ANTIBODY SCREENING; ARTICLE; BACTERIAL INFECTION; BLOOD COMPONENT; BLOOD SAFETY; BLOOD TRANSFUSION REACTION; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE MEDIATED INJURY; MAJOR CLINICAL STUDY; PATIENT SAFETY; SHELF LIFE; STATISTICAL SIGNIFICANCE; THROMBOCYTE TRANSFUSION; TRANSFUSION RELATED ACUTE LUNG INJURY;

EID: 84939514901     PISSN: 16603796     EISSN: 16603818     Source Type: Journal    
DOI: 10.1159/000381996     Document Type: Article

References (21)

1. SHOT reports 2013, 2010, 2009. www.shotuk.org/shotreports/(last accessed April 7, 2015).
2. Annual Hemovigilance Report Swissmedic 2013, 2012 www.swissmedic.ch/marktueberwachung/00138/00188/index.html?lang=en (last accessed April 7, 2015).
3. Hämovigilanzbericht 2012-Paul Ehrlich Institut. www.pei.de/haemovigilanzbericht (last accessed April 7, 2015).
4. Keller-Stanislawski B, Lohmann A, Günay S, Heiden M, Funk MB: The German haemovigilance system-reports of serious adverse transfusion reactions between 1997 and 2007. Transfus Med 2009; 19: 340-349.
5. Schosser R, Keller-Stanislawski B, Nuebling M, Loewer J: Causality assessment of suspected virus transmission by human plasma products. Transfusion 2001; 41: 1020-1029.
6. Kleinman S, Caulfield T, Chan P, Davenport R, Mc-Farland J, McPhedran S, Meade M, Morrison D, Pinsent T, Robillard P, Slinger P: Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. Transfusion 2004; 44: 1774-1789.
7. Lucas G, Rogers S, de Haas M, Porcelijn L, Bux J: Report on the Fourth International Granulocyte Immunology Workshop: progress toward quality assessment. Transfusion 2002; 42: 462-468.
8. The R Project for Statistical Computing Core Team: R: A language and environment for statistical computing. Vienna, R Foundation for Statistical Computing, 2013. www.R-project.org/(last accessed April 7, 2015).
9. Nübling CM, Heiden M, Chudy M, Kress J, Seitz R, Keller-Stanislawski B, Funk MB: Experience of mandatory nucleic acid test (NAT) screening across all blood organizations in Germany: NAT yield versus breakthrough transmissions. Transfusion 2009; 49: 1850-1858.
10. Wagner SJ: Transfusion-transmitted bacterial infection: risks, sources and interventions. Vox Sang 2004; 86: 157-163.
11. Jutzi M, Ruësch M, Mansouri Taleghani B: Einführung der Pathogeninaktivierung für Thrombozytenkonzentrate in der Schweiz. Schweiz Med Forum 2013; 13: 222-226.
12. Funk MB, Lohmann A, Serife Guenay S, Henseler O, Heiden M, Hanschmann KM, Keller-Stanislawski B: Transfusion-transmitted bacterial infections-haemovigilance data of German blood establishments (1997-2010). Transfus Med Hemother 2011; 38: 266-227.
13. de Korte D, Curvers J, de Kort WL, Hoekstra T, van der Poel CL, Beckers EA, Marcelis JH: Effects of skin disinfection method, deviation bag, and bacterial screening on clinical safety of platelet transfusions in the Netherlands. Transfusion 2006; 46: 476-485.
14. Walther-Wenke G, Wirsing von König CH, Daübener W, Heiden M, Hoch J, Hornei B, Volkers P: Monitoring bacterial contamination of blood components in Germany: effect of contamination reduction measures. Vox Sang 2011; 100: 359-366.
15. Vollmer T, Schottstedt V, Bux J, Walther-Wenke G, Knabbe C, Dreier J: Bacterial screening of platelet concentrates on day 2 and 3 with flow cytometry: the optimal sampling time point? Blood Transfus 2014; 12: 388-395.
16. Butler C, Doree C, Estcourt LJ, Trivella M, Hopewell S, Brunskill SJ, Stanworth S, Murphy MF: Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database Syst Rev 2013; 3:CD009072.
17. Chapman CE, Stainsby D, Jones H, Love E, Massey E, Win N, Navarrete C, Lucas G, Soni N, Morgan C, Choo L, Cohen H, Williamson LM; Serious Hazards of Transfusion Steering Group: Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma. Transfusion 2009; 49: 440-452.
18. Eder AF, Herron RM Jr, Strupp A, Dy B, White J, Notari EP, Dodd RY, Benjamin RJ: Effective reduction of transfusion-related acute lung injury risk with malepredominant plasma strategy in the American Red Cross (2006-2008) Transfusion 2010; 50: 1732-1742.
19. Lin Y, Hannach B, Huang MY, Saw C, Towns DK, Hannon J, Webert KE, Goldman M, Hume HA: TRALI prevention at Canadian Blood Services: the evolving process and its impact on TRALI cases in Canada. Transfusion 2009; 49(suppl 3):47A.
20. Kleinman S, Grossman B, Kopko P: A national survey of transfusion-related acute lung injury risk reduction policies for platelets and plasma in the United States. Transfusion 2010; 50: 1312-1321.
21. Gottschalk A, Van Aken H, Zenz M, Standl T: Is anesthesia dangerous? Dtsch Arztebl Int 2011; 108: 469-474.